CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC

被引：10
|
作者：
Antonia, Scott J. [1 ]
Gettinger, Scott N. [2 ]
Goldman, Jonathan [3 ]
Brahmer, Julie [4 ]
Borghaei, Hossein [5 ]
Chow, Laura Q. [6 ]
Ready, Neal E. [7 ]
Gerber, David E. [8 ]
Juergens, Rosalyn [9 ]
Shepherd, Frances [10 ]
Laurie, Scott A. [11 ]
Young, Tina [12 ]
Geese, William J. [12 ]
Agrawal, Shruti [12 ]
Li, Xuemei [12 ]
Hellmann, Matthew D. [13 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Yale Comprehens Canc Ctr, New Haven, CT USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Duke Univ, Med Ctr, Durham, NC USA
[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[9] McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada
[10] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[11] Univ Ottawa, Ctr Canc, Ottawa Hosp, Ottawa, ON, Canada
[12] Bristol Myers Squibb, Princeton, NJ USA
[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2016.09.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL01.03
引用
下载
收藏
页码：S250 / S251
页数：3
相关论文
共 50 条
  • [31] Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC
    Kahl, Kristie L.
    ONCOLOGY-NEW YORK, 2020, 34 (07): : 254 - 254
  • [32] Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA"
    Paz-Ares, Luis G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : E102 - E103
  • [33] Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Schenker, Michael
    Zurawski, Bogdan
    Kim, Sang-We
    Mahave, Mauricio
    Alexandru, Aurelia
    Peters, Solange
    Pluzanski, Adam
    Caro, Reyes Bernabe
    Linardou, Helena
    Burgers, Jacobus A.
    Nishio, Makoto
    Martinez-Marti, Alex
    Azuma, Koichi
    Axelrod, Rita
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    Li, Li
    Bushong, Judith
    Gupta, Ravi G.
    Grootendorst, Diederik J.
    Eccles, Laura J.
    Brahmer, Julie R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1055 - 1069
  • [34] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
    Chau, I.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C.
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M.
    Holtved, E.
    Murphy, M. Blum
    Abdullaev, S.
    Soleymani, S.
    Lei, M.
    Kato, K.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S379 - S380
  • [35] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Gettinger, S. N.
    Hellmann, M. D.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Nathan, F.
    Shen, Y.
    Harbison, C. T.
    Rizvi, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
  • [36] First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Urban, Laszlo
    Caro, Reyes Bernabe
    Park, Keunchil
    Sakai, Hiroshi
    Ohe, Yuichiro
    Nishio, Makoto
    Audigier-Valette, Clarisse
    Burgers, Jacobus A.
    Pluzanski, Adam
    Sangha, Randeep
    Gallardo, Carlos
    Takeda, Masayuki
    Linardou, Helena
    Lupinacci, Lorena
    Lee, Ki Hyeong
    Caserta, Claudia
    Provencio, Mariano
    Carcereny, Enric
    Otterson, Gregory A.
    Schenker, Michael
    Zurawski, Bogdan
    Alexandru, Aurelia
    Vergnenegre, Alain
    Raimbourg, Judith
    Feeney, Kynan
    Kim, Sang-We
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Hellmann, Matthew D.
    Memaj, Arteid
    Nathan, Faith Ellen
    Bushong, Judith
    Phuong Tran
    Brahmer, Julie R.
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (02) : 289 - 308
  • [37] Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
    Paly, Victoria Federico
    Hikichi, Yusuke
    Baker, Timothy
    Itakura, Eijun
    Chandran, Nisha
    Harrison, James
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1542 - 1552
  • [38] Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line (1L) Treatment (tx) of Advanced Nsclc: Overall Survival (Os) Analysis of Checkmate 817
    Fischer, Juergen R.
    Barlesi, Fabrice
    Audigier-Valette, Larisse
    Felip, Enriqueta
    Ciuleanu, Tudor-Eliade
    Jao, Kevin
    Rijavec, Erika
    Urban, Laszlo
    Aucoin, Jean-Sebastien
    Zannori, Cristina
    Vermaelen, Karim
    Aren Frontera, Osvaldo
    Ready, Neal
    Fontecedro, Alessandra Curioni
    Linardou, Helena
    Poddubskaya, Elena
    Pillai, Rathi
    Li, Sunney
    Acevedo, Angelic
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [39] Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
    Emamekhoo, Hamid
    Olsen, Mark R.
    Carthon, Bradley C.
    Drakaki, Alexandra
    Percent, Ivor J.
    Molina, Ana M.
    Cho, Daniel C.
    Bendell, Johanna C.
    Gordan, Lucio N.
    Kalebasty, Arash Rezazadeh
    George, Daniel J.
    Hutson, Thomas E.
    Arrowsmith, Edward R.
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Leung, David K.
    Tykodi, Scott S.
    CANCER, 2022, 128 (05) : 966 - 974
  • [40] Efficacy and safety of nivolumab plus ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study
    Yau, T.
    Hsu, C.
    Kang, Y.
    Kim, T.
    Hou, M.
    Lim, H.
    Chao, Y.
    Kim, Y.
    Ikeda, M.
    Choo, S.
    Neely, J.
    Shen, Y.
    Tschaika, M.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S233 - S233
12345